{
  "evolutionScenarios": [
    {
      "id": "EVOLVE001",
      "trigger": "New Evidence",
      "triggerDate": "2024-01-08",
      "evidenceSource": {
        "type": "Paper",
        "title": "Fourth-generation TKI BLU-945 overcomes C797S resistance",
        "trialId": "NCT04862780",
        "pubDate": "2023-12-15",
        "doi": "10.1056/NEJMoa2312345",
        "keyFindings": [
          "BLU-945 targets EGFR C797S mutation",
          "ORR 62% in C797S+ patients (n=85)",
          "PFS 14.5 months vs. no available therapy",
          "FDA Breakthrough Therapy designation"
        ]
      },
      "ontologyImpact": {
        "affectedClasses": ["Compound", "Alteration", "Result"],
        "affectedProperties": ["targets", "recommendedForSubgroup", "hasResult"],
        "changeType": "ADD_NEW_ENTITY"
      },
      "proposedChanges": {
        "scenario": "Scenario 1: Fully Automatic",
        "confidence": 0.95,
        "changes": [
          {
            "action": "ADD",
            "entityType": "Compound",
            "entityId": "BLU-945",
            "ttlCode": ":BLU-945 a :Compound ;\n  rdfs:label \"BLU-945\" ;\n  :compoundName \"BLU-945\" ;\n  :hasMoA :TKI ;\n  :targets :EGFR ;\n  :targetsMutation :EGFR_C797S ;\n  :fdaStatus \"Breakthrough Therapy\" ;\n  :developmentStage \"Phase I/II\" .",
            "rationale": "High-quality evidence (Phase I/II, FDA designation, peer-reviewed)"
          },
          {
            "action": "ADD",
            "entityType": "Alteration",
            "entityId": "EGFR_C797S",
            "ttlCode": ":EGFR_C797S a :Alteration ;\n  rdfs:label \"EGFR C797S\" ;\n  :inGene :EGFR ;\n  :alterationType \"Point Mutation\" ;\n  :resistance \"Post-osimertinib\" ;\n  rdfs:comment \"Tertiary resistance mutation after 3rd-gen TKI failure\" .",
            "rationale": "Critical unmet need, no previous entity in ontology"
          },
          {
            "action": "ADD",
            "entityType": "Result",
            "entityId": "RESULT_BLU945_C797S",
            "ttlCode": ":RESULT_BLU945_C797S a :Result ;\n  :aboutCancerType :NSCLC ;\n  :aboutSubgroup :NSCLC_EGFR_C797S ;\n  :aboutDrug :BLU-945 ;\n  :metric \"ORR\" ;\n  :value 62 ;\n  :unit \"%\" ;\n  :reportedIn :EVIDENCE_NCT04862780 ;\n  :evidenceLevel \"High\" ;\n  :sourceDate \"2023-12-15\"^^xsd:date .",
            "rationale": "High-quality result from Phase I/II trial"
          },
          {
            "action": "UPDATE",
            "entityType": "PatientSubgroup",
            "entityId": "NSCLC_EGFR_C797S",
            "ttlCode": ":NSCLC_EGFR_C797S a :PatientSubgroup ;\n  rdfs:label \"NSCLC with EGFR C797S\" ;\n  :hasCancerType :NSCLC ;\n  :hasAlteration :EGFR_C797S ;\n  :lineOfTherapy \"4L+\" ;\n  :recommendedDrug :BLU-945 .  # NEW PROPERTY",
            "rationale": "Connect new drug to subgroup"
          }
        ],
        "validationStatus": "PASSED",
        "shaclErrors": 0,
        "approvalRequired": false,
        "autoExecuted": true,
        "executionDate": "2024-01-08T10:30:00Z"
      },
      "impactAssessment": {
        "affectedPatients": "~30% of osimertinib-treated patients",
        "clinicalSignificance": "CRITICAL - addresses #1 unmet need",
        "ontologyVersion": "v1.0 ‚Üí v1.1",
        "backwardCompatible": true
      },
      "aiJustification": "‚úÖ AUTO-APPROVED: FDA breakthrough + peer-reviewed + SHACL valid + no conflicts"
    },
    {
      "id": "EVOLVE002",
      "trigger": "Conflicting Evidence",
      "triggerDate": "2024-01-10",
      "evidenceSource": {
        "type": "TrialSummary",
        "title": "Alectinib vs. Brigatinib in 1L ALK+ NSCLC - Head-to-head trial",
        "trialId": "NCT03456789",
        "pubDate": "2024-01-05",
        "doi": "10.1016/j.jtho.2024.01.012",
        "keyFindings": [
          "Brigatinib PFS 24.0 months vs. Alectinib 34.8 months (p=0.001)",
          "Alectinib confirmed superior to brigatinib in 1L",
          "Previous assumption: Brigatinib = Alectinib needs revision"
        ]
      },
      "ontologyImpact": {
        "affectedClasses": ["Compound", "Result"],
        "affectedProperties": ["recommendedForSubgroup", "hasResult", "priority"],
        "changeType": "UPDATE_RANKING"
      },
      "proposedChanges": {
        "scenario": "Scenario 2: AI Proposes ‚Üí Human Reviews",
        "confidence": 0.82,
        "changes": [
          {
            "action": "UPDATE",
            "entityType": "Compound",
            "entityId": "Alectinib",
            "oldTTL": ":Alectinib a :Compound ;\n  :recommendedForSubgroup :NSCLC_ALK_fusion ;\n  :lineOfTherapy \"1L\" ;\n  :priority \"High\" .  # EQUAL with Brigatinib",
            "newTTL": ":Alectinib a :Compound ;\n  :recommendedForSubgroup :NSCLC_ALK_fusion ;\n  :lineOfTherapy \"1L\" ;\n  :priority \"Highest\" ;  # UPGRADED\n  :preferredOver :Brigatinib ;\n  rdfs:comment \"Head-to-head trial NCT03456789 showed superiority\" .",
            "rationale": "Direct comparative trial overrides previous assumption of equivalence"
          },
          {
            "action": "UPDATE",
            "entityType": "Compound",
            "entityId": "Brigatinib",
            "oldTTL": ":Brigatinib a :Compound ;\n  :recommendedForSubgroup :NSCLC_ALK_fusion ;\n  :lineOfTherapy \"1L\" ;\n  :priority \"High\" .  # EQUAL with Alectinib",
            "newTTL": ":Brigatinib a :Compound ;\n  :recommendedForSubgroup :NSCLC_ALK_fusion ;\n  :lineOfTherapy \"1L, 2L\" ;  # STILL VALID for 2L\n  :priority \"High\" ;  # DOWNGRADED from Highest\n  :inferiorTo :Alectinib ;  # NEW PROPERTY\n  rdfs:comment \"Recommended for 2L or if alectinib unavailable\" .",
            "rationale": "Maintain as option but clarify hierarchy"
          }
        ],
        "validationStatus": "PENDING_HUMAN_REVIEW",
        "shaclErrors": 0,
        "approvalRequired": true,
        "reasoning": "‚ö†Ô∏è CONFLICTING DATA: Ontology assumed equivalence, new trial shows superiority. Human review needed for clinical judgment.",
        "reviewers": ["Dr. NSCLC Specialist", "Ontology Curator"],
        "reviewDeadline": "2024-01-17"
      },
      "impactAssessment": {
        "affectedPatients": "All ALK+ NSCLC 1L patients",
        "clinicalSignificance": "HIGH - affects treatment guidelines",
        "ontologyVersion": "v1.1 ‚Üí v1.2 (pending approval)",
        "backwardCompatible": true
      },
      "aiJustification": "‚ö†Ô∏è HUMAN REVIEW REQUIRED: Direct comparative data conflicts with ontology ranking. Clinical expertise needed to interpret."
    },
    {
      "id": "EVOLVE003",
      "trigger": "Real-World Data",
      "triggerDate": "2024-01-15",
      "evidenceSource": {
        "type": "Retrospective Study",
        "title": "Metformin co-administration improves EGFR TKI outcomes: 10-year real-world data",
        "journal": "Journal of Clinical Oncology",
        "pubDate": "2024-01-12",
        "doi": "10.1200/JCO.23.02345",
        "keyFindings": [
          "N=12,458 patients from 38 hospitals",
          "Metformin + EGFR TKI: PFS 16.2m vs. 13.8m (HR 0.82, p<0.001)",
          "OS improvement: 32.1m vs. 28.5m (HR 0.85, p=0.003)",
          "Effect consistent across all EGFR mutations"
        ]
      },
      "ontologyImpact": {
        "affectedClasses": ["Compound", "CombinationTherapy"],
        "affectedProperties": ["hasSynergy", "recommendedCombination"],
        "changeType": "ADD_COMBINATION"
      },
      "proposedChanges": {
        "scenario": "Scenario 3: AI Proposes ‚Üí Human OK ‚Üí Gens Auto-commits",
        "confidence": 0.88,
        "changes": [
          {
            "action": "ADD",
            "entityType": "CombinationTherapy",
            "entityId": "Metformin_EGFR_TKI",
            "ttlCode": ":Metformin_EGFR_TKI a :CombinationTherapy ;\n  rdfs:label \"Metformin + EGFR TKI\" ;\n  :hasComponent :Metformin, :EGFR_TKI ;\n  :synergy \"Positive\" ;\n  :synergyMechanism \"AMPK activation inhibits mTOR pathway\" ;\n  :evidenceLevel \"High\" ;\n  :evidenceType \"Real-World Data\" ;\n  :sampleSize 12458 ;\n  :hazardRatio 0.82 ;\n  :pValue \"<0.001\"^^xsd:string ;\n  :recommendedFor :NSCLC_EGFR_mutant ;\n  :cost \"Low\" ;\n  rdfs:comment \"Large real-world study validates preclinical hypothesis\" .",
            "rationale": "High-quality RWD (n>10,000) validates previous hypothesis (HIDDEN001)"
          },
          {
            "action": "UPDATE",
            "entityType": "Compound",
            "entityId": "Metformin",
            "newTTL": ":Metformin a :Compound ;\n  rdfs:label \"Metformin\" ;\n  :primaryIndication \"Type 2 Diabetes\" ;\n  :secondaryIndication \"NSCLC adjuvant therapy\" ;  # NEW\n  :recommendedCombination :EGFR_TKI ;  # NEW\n  :cost \"Very Low\" ;\n  :safetyProfile \"Excellent\" .",
            "rationale": "Upgrade status from 'repurposing candidate' to 'validated combination'"
          },
          {
            "action": "ADD",
            "entityType": "Rule",
            "entityId": "RULE_Metformin_Recommendation",
            "ttlCode": "# SWRL Rule\n:RULE_Metformin_Recommendation a :InferenceRule ;\n  rdfs:label \"Recommend Metformin for EGFR+ patients\" ;\n  :ruleBody \"\"\"\n    ?patient :hasAlteration ?alt .\n    ?alt :inGene :EGFR .\n    ?patient :isReceiving ?tki .\n    ?tki :hasMoA :TKI .\n  \"\"\" ;\n  :ruleHead \"\"\"\n    ?patient :shouldConsider :Metformin .\n    :Metformin :recommendedFor ?patient .\n  \"\"\" ;\n  :confidence 0.88 ;\n  :evidenceSource \"JCO 2024\" .",
            "rationale": "Automate recommendation in reasoning engine"
          }
        ],
        "validationStatus": "AWAITING_HUMAN_OK",
        "shaclErrors": 0,
        "approvalRequired": true,
        "reasoning": "‚úÖ HIGH-QUALITY RWD: Large sample, significant results, validates hypothesis. Recommend human OK then auto-commit.",
        "humanDecision": "APPROVED",
        "humanApprover": "Dr. Clinical Curator",
        "approvalDate": "2024-01-16T14:20:00Z",
        "autoCommit": true,
        "commitMessage": "feat(ontology): Add Metformin+EGFR TKI combination based on RWD (JCO 2024, n=12458)",
        "executionDate": "2024-01-16T14:21:00Z"
      },
      "impactAssessment": {
        "affectedPatients": "All EGFR+ NSCLC patients (millions globally)",
        "clinicalSignificance": "HIGH - low-cost intervention with proven benefit",
        "ontologyVersion": "v1.2 ‚Üí v1.3",
        "backwardCompatible": true
      },
      "aiJustification": "‚úÖ RECOMMENDED FOR APPROVAL: RWD validates preclinical hypothesis. Low risk (metformin is safe), high benefit (PFS/OS improvement)."
    },
    {
      "id": "EVOLVE004",
      "trigger": "Safety Signal",
      "triggerDate": "2024-01-20",
      "evidenceSource": {
        "type": "FDA Safety Alert",
        "title": "Hepatotoxicity signal with Drug_X in combination with osimertinib",
        "source": "FDA MedWatch",
        "pubDate": "2024-01-18",
        "keyFindings": [
          "15 cases of Grade 3-4 hepatotoxicity",
          "Drug_X + osimertinib combination",
          "FDA recommends avoiding combination pending investigation"
        ]
      },
      "ontologyImpact": {
        "affectedClasses": ["CombinationTherapy", "Compound"],
        "affectedProperties": ["contraindication", "warning"],
        "changeType": "ADD_WARNING"
      },
      "proposedChanges": {
        "scenario": "Scenario 1: Fully Automatic (Safety-critical)",
        "confidence": 1.0,
        "changes": [
          {
            "action": "UPDATE",
            "entityType": "Compound",
            "entityId": "Drug_X",
            "newTTL": ":Drug_X a :Compound ;\n  :contraindication :Osimertinib ;  # NEW\n  :warning \"Hepatotoxicity risk when combined with osimertinib (FDA 2024)\" ;\n  :fdaAlert \"MedWatch 2024-01-18\" ;\n  :status \"Under Investigation\" .",
            "rationale": "FDA safety alert requires immediate action"
          },
          {
            "action": "DELETE",
            "entityType": "CombinationTherapy",
            "entityId": "Drug_X_Osimertinib",
            "rationale": "Remove unsafe combination from recommendations"
          }
        ],
        "validationStatus": "PASSED",
        "shaclErrors": 0,
        "approvalRequired": false,
        "autoExecuted": true,
        "executionDate": "2024-01-20T09:00:00Z",
        "urgency": "CRITICAL"
      },
      "impactAssessment": {
        "affectedPatients": "Patients on Drug_X + osimertinib",
        "clinicalSignificance": "CRITICAL - patient safety",
        "ontologyVersion": "v1.3 ‚Üí v1.3.1 (hotfix)",
        "backwardCompatible": false
      },
      "aiJustification": "üö® AUTO-EXECUTED (SAFETY): FDA alert requires immediate removal from recommendations. No human review delay for patient safety."
    }
  ],
  "workflows": {
    "scenario1_FullyAutomatic": {
      "name": "Fully Automatic Update",
      "triggers": [
        "High-confidence evidence (>0.9)",
        "FDA approval/breakthrough",
        "Safety alerts (critical)",
        "SHACL validation passes",
        "No conflicts with existing knowledge"
      ],
      "steps": [
        "1. Evidence ingestion (Hydrate)",
        "2. AI impact analysis",
        "3. Generate TTL changes",
        "4. SHACL validation",
        "5. Conflict detection",
        "6. Auto-commit to ontology",
        "7. Notify curators (post-hoc review)"
      ],
      "confidence_threshold": 0.9,
      "approval_required": false,
      "typical_use_cases": [
        "New FDA-approved drug",
        "Safety alerts",
        "High-quality RCT results"
      ]
    },
    "scenario2_HumanReview": {
      "name": "AI Proposes ‚Üí Human Reviews ‚Üí Human Uploads TTL",
      "triggers": [
        "Medium confidence (0.7-0.9)",
        "Conflicting evidence",
        "Ranking/priority changes",
        "Complex clinical judgment needed"
      ],
      "steps": [
        "1. Evidence ingestion (Hydrate)",
        "2. AI generates proposal",
        "3. Show old vs. new TTL diff",
        "4. Human curator reviews",
        "5. Human edits TTL if needed",
        "6. Human uploads revised TTL",
        "7. System validates & commits"
      ],
      "confidence_threshold": 0.7,
      "approval_required": true,
      "typical_use_cases": [
        "Head-to-head trial results",
        "Conflicting study outcomes",
        "Guideline changes"
      ]
    },
    "scenario3_HumanOK_AutoCommit": {
      "name": "AI Proposes ‚Üí Human OK ‚Üí Gens Auto-commits",
      "triggers": [
        "High-quality evidence (0.8-0.9)",
        "RWD with large sample",
        "Validates existing hypothesis",
        "Low risk of error"
      ],
      "steps": [
        "1. Evidence ingestion (Hydrate)",
        "2. AI generates complete TTL",
        "3. SHACL pre-validation",
        "4. Human reviews proposal (no editing)",
        "5. Human clicks 'Approve' or 'Reject'",
        "6. If approved: System auto-commits",
        "7. Git commit message auto-generated"
      ],
      "confidence_threshold": 0.8,
      "approval_required": true,
      "typical_use_cases": [
        "Large RWD studies",
        "Meta-analyses",
        "Hypothesis validation"
      ]
    }
  },
  "versionControl": {
    "current_version": "v1.3.1",
    "history": [
      {
        "version": "v1.0",
        "date": "2024-01-01",
        "changes": "Initial NSCLC EGFR/ALK ontology",
        "commit": "abc123"
      },
      {
        "version": "v1.1",
        "date": "2024-01-08",
        "changes": "Added BLU-945 and EGFR C797S (EVOLVE001)",
        "commit": "def456",
        "trigger": "New Evidence",
        "workflow": "Fully Automatic"
      },
      {
        "version": "v1.2",
        "date": "2024-01-11",
        "changes": "Updated Alectinib/Brigatinib ranking (EVOLVE002)",
        "commit": "ghi789",
        "trigger": "Conflicting Evidence",
        "workflow": "Human Review"
      },
      {
        "version": "v1.3",
        "date": "2024-01-16",
        "changes": "Added Metformin+EGFR TKI combination (EVOLVE003)",
        "commit": "jkl012",
        "trigger": "Real-World Data",
        "workflow": "Human OK + Auto-commit"
      },
      {
        "version": "v1.3.1",
        "date": "2024-01-20",
        "changes": "Removed Drug_X+Osimertinib combination (safety alert)",
        "commit": "mno345",
        "trigger": "Safety Signal",
        "workflow": "Fully Automatic",
        "urgency": "CRITICAL"
      }
    ]
  },
  "metrics": {
    "totalEvolutions": 4,
    "fullyAutomatic": 2,
    "humanReview": 1,
    "humanOK_autoCommit": 1,
    "avgConfidence": 0.91,
    "avgTimeToUpdate": "2.3 days",
    "shaclValidationRate": "100%"
  }
}
